4. Vanda Pharmaceuticals (VNDA) has an unusual model for biotech. Rather than licensing internal research to larger pharmaceutical companies, it in-licensed two pipeline candidates from established peers. Fanapt, an anti-schizophrenia drug, was approved in May 2009 by the Food and Drug Administration. Thus, Vanda's strategy has worked so far, but it must pay hefty royalties on approved drug Fanapt to partner Novartis. Its other candidate, Tasimelteon, is for sleep and mood disorders, with potential applications for insomnia and depression.
Morningstar is less optimistic about Tasimelteon's potential than it is about Fanapt's. And Fanapt is entering a heavily contested anti-psychotic drug market. Nevertheless, prescriptions continue to strengthen on a month-over-month basis.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV